Literature DB >> 34805576

The value of liquid biopsy in the diagnosis and staging of hepatocellular carcinoma: a systematic review.

Poh Tan1, Lisa Grundy1, Peter Makary1, Khem Hua Eng2, George Ramsay3, Mohamed Bekheit1,4.   

Abstract

BACKGROUND: Blood-borne tumour markers in the form of circulating tumour cells (CTCs) are of intense research interest in the diagnostic and prognostic work-up of hepatocellular carcinoma (HCC).
METHODS: This is a meta-analysis. Using a PICO strategy, adults with HCC was the population, with the individual CTCs as the intervention and comparators. The primary outcome was the sensitivity and specificity of HCC detection with tumour specific single gene methylation alteration. Secondary outcomes were the comparison using specific assay methods and the effect of early vs. late stages on CTC positivity. We included patients with HCC who had samples taken from peripheral blood and had sufficient data to assess the outcome data. ASSIA, Cochrane library, EMbase, Medline, PubMed and the knowledge network Scotland were systematically searched with appropriate Mesh terms employed. The quality assessment of diagnostic accuracy studies (QUADAS) was used to ensure quality of data. Statistical analysis was performed using the 'Rev Man' meta-analysis soft ward for Windows.
RESULTS: The review included 36 studies, with a total of 5,853 patients. Here, we found that AFP has the highest overall diagnostic performance. The average Youden index amongst all CTC was 0.46 with a mode and median of 0.5 with highest of 0.87 and lowest of 0.01.
CONCLUSIONS: The available literature provides weak evidence that there is potential in the use of CTC, however the lack of a standardised procedure in the study of CTC contribute to the lack of consensus of use. Future research should include large scaled, standardized studies for the diagnostic accuracy of CTCs. 2021 Translational Gastroenterology and Hepatology. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); circulating tumour cells (CTCs); liquid biopsy; tumour markers

Year:  2021        PMID: 34805576      PMCID: PMC8573369          DOI: 10.21037/tgh.2020.01.11

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  52 in total

1.  The PICO strategy for the research question construction and evidence search.

Authors:  Cristina Mamédio da Costa Santos; Cibele Andrucioli de Mattos Pimenta; Moacyr Roberto Cuce Nobre
Journal:  Rev Lat Am Enfermagem       Date:  2007 May-Jun

2.  Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.

Authors:  Abeer A Bahnassy; Abdel-Rahman N Zekri; Ahmed El-Bastawisy; Amal Fawzy; Marwa Shetta; Nehal Hussein; Dalia Omran; Abdallah A S Ahmed; Samir S El-Labbody
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

3.  The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma.

Authors:  Ning Ren; Lun-Xiu Qin; Hong Tu; Yin-Kun Liu; Bo-Heng Zhang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2006-02-25       Impact factor: 4.553

4.  MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma.

Authors:  Xiang-Fen Ji; Yu-Chen Fan; Shuai Gao; Yang Yang; Jian-Jun Zhang; Kai Wang
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

5.  High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.

Authors:  Winnie Yeo; Nathalie Wong; Wai-Lap Wong; Paul B S Lai; Sheng Zhong; Philip J Johnson
Journal:  Liver Int       Date:  2005-04       Impact factor: 5.828

6.  Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma.

Authors:  Ken Chen; Hong Zhang; Li-Na Zhang; Shao-Qing Ju; Jing Qi; Dong-Feng Huang; Feng Li; Qun Wei; Jing Zhang
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

7.  Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer.

Authors:  Giovanna Vona; Laurence Estepa; Christophe Béroud; Diane Damotte; Frédérique Capron; Bertrand Nalpas; Alexandra Mineur; Dominique Franco; Bernard Lacour; Stanislas Pol; Christian Bréchot; Patrizia Paterlini-Bréchot
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

8.  Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA.

Authors:  Rufina Igetei; Jesse A Otegbayo; Dennis A Ndububa; Olufunmilayo A Lesi; Chiaka I Anumudu; Pierre Hainaut; Emmanuelle Gormally
Journal:  Ann Hepatol       Date:  2008 Oct-Dec       Impact factor: 2.400

9.  Detection of aberrant p16INK4A methylation in sera of patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  Hyung Jun Chu; Jeong Heo; Soo Boon Seo; Gwang Ha Kim; Dae Hwan Kang; Geun Am Song; Mong Cho; Ung Suk Yang
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

10.  Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma.

Authors:  Li-Yan Han; Yu-Chen Fan; Nan-Nan Mu; Shuai Gao; Feng Li; Xiang-Fen Ji; Cheng-Yun Dou; Kai Wang
Journal:  Int J Med Sci       Date:  2014-01-07       Impact factor: 3.738

View more
  1 in total

Review 1.  Liquid biopsies to occult brain metastasis.

Authors:  Asad Ur Rehman; Parvez Khan; Shailendra Kumar Maurya; Jawed A Siddiqui; Juan A Santamaria-Barria; Surinder K Batra; Mohd Wasim Nasser
Journal:  Mol Cancer       Date:  2022-05-10       Impact factor: 41.444

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.